SHANGHAI, June 24, 2022 /PRNewswire/ — Sanyou Biopharmaceuticals, a high-tech biologics company focused on R&D and services of innovative antibody drugs, and Dragon Sail Pharmaceutical, a CDMO and the CMO business dedicated to providing world-class high-end biologic drug manufacturing services, announced the implementation of a long-term strategic partnership. Both parties will share experiences and technical advantages, and provide integrated and modular solutions that cover R&D of biological drugs, CDMO and commercial productions to the global biopharmaceutical industry.
Aimed at providing high-quality, high-efficiency and cost-effective drug development and manufacturing services to pharmaceutical and biotechnology companies, the two companies will invest their advantageous resources, expertise and experience in this strategic partnership to lead a in-depth collaboration in the field. drug discovery, drug development and CDMO. Sanyou will provide preclinical R&D services, including drug screening, pharmacology research, process development and quality control of various biological drugs, including monoclonal antibodies, multispecific antibodies, ADC drugs, etc. . Dragon Sail will provide services for pilot production, clinical sample production, scale process development and commercial production of various biological drugs.
Dragon Sail Pharmaceutical is a leading CDMO enterprise for the production of biological drugs in China, is committed to providing one-stop R&D and manufacturing outsourcing services from sequence to IND, and clinical sample production to BLA and commercial production. With a total investment of 690 million RMB and a total production scale of up to 12000L, the company site is built and operated in accordance with cGMP requirements of NMPA and FDA and has passed EU QP audit, which qualifies for different stages production of clinical samples and commercial drugs. The company has a professional technical team of more than 200 people, with team members from well-known domestic and international pharmaceutical companies and universities. 90% of current employees are technical R&D professionals and about 40% of employees have master’s and doctoral degrees. Equipped with advanced NONCROS® uncrossed antibody production technology, Dragon Sail has provided high quality and efficient R&D and manufacturing services to more than 10 pharmaceutical companies for various biologic drug projects.
Sanyou Biopharmaceuticals is a high-tech biological company that focuses on the R&D and services of innovative antibody drugs. Sanyou has established an innovative integrated antibody drug R&D laboratory of more than 20,000 square meters with state-of-the-art facilities in Shanghai’s Caohejing High-tech Park. Driven by the excellent innovation platforms of Super-Trillion Innovative Antibody Drug Discovery Platform, Integrated Innovative Antibody Drug R&D Platform and Intelligent Innovative Antibody Drug R&D Platform, Sanyou has 10 major functional modules and more than 40 technology platforms core covering pre-clinical R&D, and has a professional team of more than 250 people, more than 70% of whom hold PhD or master’s degrees. Sanyou has provided innovative high-quality and high-efficiency antibody drug development solutions, organized services and collaborative R&D to more than 300 companies and organizations worldwide, and several of the above drug development projects have entered into the clinical phases.
“We are honored to deepen and expand our collaboration with Sanyou,” said Kai Tan, CEO of Dragon Sail Pharmaceutical. “Sanyou has accumulated a wealth of successful experience in antibody drug discovery and development. Dragon Sail Pharmaceutical has established a GMP cross-free manufacturing base in Lingang New District and built a systematic development for antibody drugs from DNA to BLA.The collaboration between the two parties will provide a powerful engine for the successful development of antibody drugs, accelerate the new drug development process, empower partners and benefit both more patients.”
“We highly value our strategic partnership with Dragon Sail Pharmaceutical.” said Guojun Lang, CEO of Sanyou Biopharmaceuticals. “Dragon Sail’s robust CMC antibody drug development and GMP manufacturing platform has been recognized by the industry. Sanyou has excellent innovative drug discovery and preclinical R&D capabilities, and our proprietary super-trillion innovative antibody drug discovery platform integrates nine kinds of super-trillion innovative antibody libraries with library capacity cumulative up to ten trillion, and a high-throughput automated screening system. Sanyou will combine the technical advantages with Dragon Sail Pharmaceutical to provide more comprehensive and high-quality one-stop services for our customers.
About Dragon Sail Pharmaceutical
Dragon Sail was established in 2016, directly invested by Guilin Sanjin Pharmaceutical Company Limited, and is one of Sanjin’s wholly owned subsidiaries. Dragon Sail’s goal is to create high-end cGMP monoclonal antibody drug and commercial manufacturing sites in Lingang Science Blue Bay (Shanghai). The total investment of this manufacturing site is approximately 690 million yuan. The manufacturing scale of the first phase is 3*2000L, and the second phase could reach the scale of 6*2000L. Dragon Sail provides one-stop CDMO services for antibody drugs, from CMC development to commercial production, the Blue Bay site is one of the largest monoclonal antibody production bases in Shanghai.
About Sanyou Biopharmaceuticals
Sanyou Biopharmaceuticals Co., Ltd. is a biological high-tech company focused on the R&D and services of innovative antibody drugs. Sanyou is committed to establishing a high-quality, high-throughput and leading integrated R&D and value-processing platform for innovative antibodies internationally, by building a business ecosystem involving products and services therapy, R&D, and diagnostics, and by cooperating with biopharmaceutical, diagnostic, and pharmaceutical R&D companies to make new advances in the diagnosis and treatment of human diseases. Sanyou has established an integrated antibody innovative R&D laboratory of more than 20,000 square meters with advanced facilities and equipment, and more than 40 core innovation technology platforms, including the discovery of innovative antibodies with a series of trillion phage display antibody libraries, innovative antibody optimization, cell line construction, upstream and downstream process development, preclinical R&D and industrial development.
Show original content to download multimedia:https://www.prnewswire.com/news-releases/sanyou-biopharmaceuticals-forged-strategic-partnership-with-dragon-sail-pharmaceutical-to-upgrade-integrated-innovative-antibody-drug-rd-301574607.html
SOURCESanyou Biopharmaceuticals
